MindGenix services are conducted from facilities in Israel. Combining staff expertise with the impressive barrier facilities ensures that we provide dependable, high-quality research performance. All studies are personally supervised by experts in the field who are able to provide depth of experience working with the PS1/APP model over the last several years.

We are a specialized preclinical neurosciences contract research service organization giving our pharmaceutical clients the ability to optimize their drug selection and development programs in Alzheimer’s disease (“AD”) and in related disease indications. Our core technology resource is a double transgenic mouse model that exhibits a well-characterized phenotype that is highly consistent with several key features of human AD. The model is useful for testing new compounds against a variety of therapeutic targets which can also be validated using this model.

Our highly trained team of neuroscientists and business professionals provide our clients with an outstanding quality of service and expertise that is unmatched in the industry. In particular, our clients benefit from turn-key services which includes a wide-range of special drug testing services including behavioral, neuropathological, biochemical, electrophysiological and other methods of analysis. Studies are blinded, data securely stored and reported in detailed reports during and after the study.

MindGenix has its corporate headquarters in New York and its drug testing services division in Israel. Its transgenic animal testing services are provided on a fee-for-service basis with no downstream milestone or royalties payments

Licensing & Royalty Free

With contract services through MindGenix, not only do you gain access to the PS1/APP model and the expertise of our team of partners, you do it without the on-going financial burden of licensing or the expense and resources required to develop equivalent capabilities in house.

• No royalties or downstream fees
• No milestone payments to worry about
• Minimized internal development cost and manpower burden
 

Turn-Key Solutions

MindGenix provides a comprehensive, turn-key service to rapidly screen and evaluate new drug candidates for Alzheimer's disease, including treatment, tissue preparation (fixation and/or freezing), high-throughput sectioning using NeuroScience Associates' MultiBrain™ technology, digitized neuropathology, quantitative ß-amyloid determination using MindGenix's validated ELISA assay, and behavioral studies. Through MindGenix, drug effects can be measured in less than 4 months from study initiation, providing data on amyloid burden, markers of oxidative stress and inflammation, neurodegeneration, and behavioral impairment.